High-titer Japanese encephalitis virus genotype V and its use
By inoculating Japanese encephalitis virus genotype V into mouse brains and subculturing in Vero cells, a high-titer strain (K15P38-KNIH) is produced, addressing the threat of genotype V with improved growth and immunogenicity for effective vaccine development.
Patent Information
- Application Number
- JP2024533111
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-08
- Filing Date
- 2023-04-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-04-18
AI Technical Summary
The emergence of Japanese encephalitis virus genotype V poses a threat as it could replace existing strains, necessitating the development of a vaccine candidate with improved proliferation rates to prepare for potential outbreaks.
The development of high-titer Japanese encephalitis virus genotype V (K15P38-KNIH) is achieved by inoculating the virus into mouse brains and subculturing it in Vero cells, resulting in a strain with genetic mutations that maintain immunogenicity and higher titers.
The K15P38-KNIH strain exhibits enhanced growth rates and maintains immunogenicity, making it a more effective vaccine candidate against Japanese encephalitis, with comparable immunogenicity and neutralizing antibody responses to the original virus.
Smart Images

Figure 2024541677000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a high-titer Japanese encephalitis virus genotype V and uses thereof. [Background technology]
[0002] Japanese encephalitis is a zoonotic disease that is transmitted by mosquitoes and causes encephalitis accompanied by high fever and coma in humans, ultimately leading to death. In Korea and Japan, Japanese encephalitis is known to be transmitted by Culex tritaeniorhynchus, but in Southeast Asia, including China and India, Culex annulus, Culex pipiens, Culex gelidus and Anopheles spp. are also known to transmit the Japanese encephalitis virus. Unlike adults who show asymptomatic infection, children under 14 years of age and the elderly suffer from high fever, headache, sensory abnormalities, impaired consciousness, coma and death, and during the recovery period, they show aftereffects such as speech disorder and impaired judgment. Livestock animals, including pigs, horses, cows, sheep and goats, wild birds, such as pigeons and blue herons, and reptiles are susceptible to this disease. In particular, pigs are known to be an amplifying host for the Japanese encephalitis virus and are an important animal to be immunized against in public health. When Japanese encephalitis virus infects adult and fattening pigs by mosquitoes, it does not show any clinical symptoms even if it causes viremia, but when pregnant pigs are infected with Japanese encephalitis, it induces reproductive disorders such as premature birth, miscarriage, and birth of weak piglets with neurological symptoms. In boars, it invades the reproductive tract and inhibits spermatogenesis, decreasing sperm count and increasing abnormal sperm, lowering the conception rate.
[0003] In Korea, Japanese encephalitis is a zoonotic disease transmitted by mosquitoes that has been occurring continuously since 1950, mainly in Southeast Asia, including China, Japan, and Korea. However, it has also been reported in other regions outside Asia, such as Australia, Africa, and Russia, and is recognized as an emerging new infectious disease. In humans, more than 67,900 cases are reported annually in Asia alone, of which about 5,000 people die. In particular, recent global warming and climate change, in addition to the development of agricultural irrigation channels and the specialization and large-scale of agriculture, have changed the ecological environment of mosquitoes, which are vectors of the disease, and may have a significant impact on the transmission of Japanese encephalitis, making it even more of a problem. In addition, when pigs are infected with the Japanese encephalitis virus, they show viremia for 2 to 3 days, and if a mosquito bites blood during this period, a large amount of the virus is transferred to the mosquito. After about 10 days in the mosquito's body, the Japanese encephalitis virus transferred from the pig can infect other animals and humans through the mosquito's salivary glands. Therefore, prevention of Japanese encephalitis and the development of immunity in pigs, which are amplification hosts, are extremely important for the control of Japanese encephalitis in humans.
[0004] The Japanese encephalitis virus currently prevalent in Korea is genotype I, and the vaccine is being administered against genotype III. In 2015, genotype V was isolated for the first time from a patient infected with Japanese encephalitis virus in Korea (isolated strain name: K15P38), raising concerns that existing prevalent viruses may be replaced. Therefore, it is necessary to prepare for the replacement of new genotypes (V types), and the present invention aims to develop a vaccine candidate substance using genotype V viruses isolated from patients.
[0005] Patent Document 1 relates to a vaccine composition for preventing Japanese encephalitis in pigs, containing a purified genotype 1 Japanese encephalitis virus, and discloses a purified genotype 1 Japanese encephalitis virus KV1899-120P (accession number: KCTC18347P) and a vaccine composition containing the same. Patent Document 2 discloses an inactivated Japanese encephalitis vaccine composition containing a Japanese encephalitis virus KV1899 strain antigen inactivated with BEI and a porcine GM-CSF recombinant protein.
[0006] However, the high-titer Japanese encephalitis virus genotype V of the present invention and its use are not disclosed. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] Korean Patent Registration No. 1642705 [Patent Document 2] Korean Patent No. 1484605 Summary of the Invention [Problem to be solved by the invention]
[0008] In order to solve the above problems, the present invention aims to prepare for the outbreak of a new Japanese encephalitis virus genotype, type V, by using viruses obtained from Japanese encephalitis patients in Japan, to obtain high-titer viruses with improved proliferation rates in cells, and to develop these as candidate vaccine substances. [Means for solving the problem]
[0009] To achieve the objectives of the present invention, the present invention provides a high-titer Japanese encephalitis virus genotype V K15P38-KNIH.
[0010] The Japanese encephalitis virus of the present invention, named K15P38-KNIH, is derived from the Japanese encephalitis virus that has recently been prevalent in Japan. The K15P38 virus strain was subcultured in Vero cells to obtain the K15P38-V25 virus strain, which was then inoculated into the brain of a mouse to finally produce the virus. The genome sequence analysis result is the same as sequence number 1.
[0011] The Japanese encephalitis virus may have the accession number KCTC15027BP.
[0012] The high titer is 1×10 8It may be more than pfu / mL.
[0013] In another example of the present invention, the present invention provides a method for producing high-titer Japanese encephalitis virus genotype V K15P38-KNIH, comprising the steps of inoculating an isolated Japanese encephalitis virus into a mouse cerebrum; and obtaining the Japanese encephalitis virus from the mouse cerebrum.
[0014] The isolated Japanese encephalitis virus may be Japanese encephalitis virus genotype V, the method may further include a step of subculturing the virus in Vero cells, and the inoculation may be performed two or more times.
[0015] In another embodiment of the present invention, the present invention provides a vaccine composition comprising the Japanese encephalitis virus.
[0016] The vaccine composition may further comprise a pharma- ceutically acceptable carrier or excipient in addition to the virus. Suitable carriers for vaccines are known to those skilled in the art and include, but are not limited to, proteins, sugars, and the like. The carrier may be an aqueous or non-aqueous solution, suspension, or emulsion. Examples of non-aqueous carriers include propylene glycol, polyethylene glycol, edible oils, e.g., olive oil, and injectable organic esters, e.g., ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Parenteral carriers include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous carriers include electrolyte supplements, such as those based on Ringer's dextrose, fluids, and nutritional supplements. Preservatives and other additives may include, for example, antimicrobial agents, antioxidants, chelating agents, inert gases, and the like. Preferred preservatives include formalin, thimerosal, neomycin, polymyxin B, and amphotericin B.
[0017] The vaccine composition may further include an adjuvant (immunocomposition agent, immune enhancing agent) in the form of a diluent.
[0018] The adjuvant refers to a compound or mixture that enhances immune response and / or accelerates absorption rate after vaccination, including any absorption enhancer. Acceptable adjuvants include, but are not limited to, Freund's complete adjuvant, Freund's incomplete adjuvant, saponin, mineral gel, such as aluminum hydroxide, surfactants, such as lysolecithin, fluoron polyol, polyanion, peptide, oil or hydrocarbon emulsion, keyhole limpet hemocyanin, dinitrophenol, etc. A preferred adjuvant is MONTANIDE IMS1313 adjuvant manufactured by SEPPIC.
[0019] The dose of the vaccine composition for the purpose of the present invention can be adjusted depending on the condition of the subject, the administration route and the administration form, and is not limited. Those skilled in the art of the present invention can obviously use it within various ranges depending on the symptoms. Generally, in the present invention, the experimental effective amount is 0.01 to 1 mL (10 5.0 TCID 50 / mL or more), preferably 0.01 to 0.03 mL per kg of body weight per day, can be administered continuously or intermittently.
[0020] The vaccine composition of the present invention can be administered via administration routes such as oral, intramuscular, subcutaneous, peritoneal, intravenous, dermal, ocular, and intracerebral, but is not limited thereto, and is preferably administered via intramuscular administration route.
[0021] In yet another embodiment of the present invention, there is provided a method for vaccinating a non-human animal against Japanese encephalitis, comprising the step of administering the vaccine composition to a non-human animal. Effect of the Invention
[0022] In the present invention, in order to improve the growth rate of vaccine strains, which is an essential condition for industrial use in vaccine development, a human isolated strain was repeatedly inoculated into animal cells and mouse brains to obtain a high-titer virus. Although the growth-improved strain has some genetic mutations, it maintains its immunogenicity compared to the original virus, making it more useful as a vaccine candidate strain. [Brief description of the drawings]
[0023] [Figure 1] FIG. 1 shows a comparison of the proliferation rates of Japanese encephalitis viruses K15P38-V25 and K15P38-KNIH. [Diagram 2] A figure showing a comparison of immunogenicity between Japanese encephalitis virus K15P38-V25 and K15P38-KNIH viruses. IgG ELISA of serum inoculated with each virus. (A) Original Japanese encephalitis virus attached, (B) K15P38-KNIH virus attached, control group (Ctrl) is non-immune mouse serum. [Diagram 3] FIG. 1 shows the results of analyzing serum neutralizing antibody titers after inoculation with Japanese encephalitis virus K15P38-KNIH. [Figure 4] This figure shows the results of confirming an increase in immunoglobulin antibody titer (total IgG) in groups vaccinated with Japanese encephalitis virus genotypes III and V antigens (8 ug / dose) when the same antigen was vaccinated twice. [Diagram 5] FIG. 1 shows the results of determining neutralizing antibody titers (ND50, Karber formula) using mouse sera induced by genotype V immunizing antigens. BEST MODE FOR CARRYING OUT THEINVENTION
[0024] The present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
[0025] <Example 1> Method for producing Japanese encephalitis virus strain 1) Subcultured strain (K15P38-V25) To produce high titers of the genotype V Japanese encephalitis virus strain K15P38, we performed repeated subculture experiments in Vero cells. The K15P38 virus strain is the original virus isolated from a patient. Vero (derived from monkey kidney epithelial cells) cells were cultured at 5×10 6 K15P38-V25 was produced by inoculating cells / 75 flasks. After 24 hours, the cells were washed twice with DPBS, and then 200 μL was inoculated into 3 mL of serum-free MEM medium and cultured for 1 hour at 5% CO2. 6 mL of 2% serum MEM was added to the total culture medium, and the cells were cultured for 48 hours at 5% CO2. This process was repeated for 25 passages to produce K15P38-V25.
[0026] 2) Mouse cerebral inoculation strain (K15P38-KNIH) This experiment was conducted to produce high titer virus by repeatedly injecting K15P38-V25 virus into the brain of BALB / c mice. Five female mice were prepared per set, and anesthetized by intramuscular injection using an anesthetic (Zoletil: 50μL / kg, Rompun: 10mg / kg mixture). A 1cm incision was made in the skin of the head, and the mouse's head was fixed in a deep brain fixation device for small animals (Stereotaxic). After confirming the above (bregma), a hole was made in the right skull at the hippocampus, and 5μL of K15P38-V25 was administered over 2 minutes (2.5μL / min). The skin was sutured, and recovery was induced. Disease monitoring was confirmed from K15P38-V25 administration (day 0) to days 5-6. If abnormal symptoms (piloerection, abnormal gait, extension) occurred, the mouse brain tissue was removed. The brain tissue was added with 1 mL of PBS, and after the tissue was crushed, centrifuged (12,000 rpm, 20 minutes), the separated supernatant was inoculated into the mouse again, and the process was repeated.
[0027] <Example 2> Confirmation of virus titer by cell passage culture and repeated inoculation into mouse brain 1) Confirmation of virus titer using plaque assay experiment method The titers of the virus obtained by passage culture using Vero cells and repeated inoculation into the brain after passage culture in Vero cells were compared. The Japanese encephalitis genotype V isolate was passage cultured only in cells (black blocks in Figure 1). After passage culture in cells was repeated 1, 20, and 25 times, the maximum titer was 6.5 × 10 6 pfu / mL, but after repeated inoculation into mouse brains, the proliferation rate improved with one, three, and five subcultures on Vero cells (white blocks in Figure 1), and the titer was 1.15 × 10 8 It was confirmed that the pfu / mL.
[0028] When the clinical specimen isolated virus (K15P38) was passage-cultured in Vero cells (name: K15P38-V25), it was difficult to improve the growth rate, but after subsequent inoculation into mouse brains (name: K15P38-KNIH, accession number: KCTC15027BP), the growth rate was improved and a high titer was obtained. After repeated passage inoculation into mouse brains, a high titer of the virus was confirmed even with a short passage in cells, compared to the titer of the virus passage-cultured in cells (Figure 1).
[0029] <Example 3> Confirmation of genetic mutations in K15P38-V25 and K15P38-KNIH viruses 1) Analysis of full-length gene mutations of Japanese encephalitis virus · To analyze the base sequence of the Japanese encephalitis virus that was subcultured in Vero cells (subcultures 1 and 25) and repeatedly inoculated into the brain to obtain a high-titer virus, full-length gene mutations were analyzed using Blast 2 sequence. As a result of the analysis, it was confirmed that the identity of the Japanese encephalitis virus DNA was 98% (10925 / 10945) and that there were some gene mutations (Table 1). The sequence of the final virus strain (K15P38-KNIH) obtained is the same as SEQ ID NO: 1 below. JPEG2024541677000002.jpg154170
[0030] [SEQ ID NO: 1] K15P38-KNIH full-length genome sequence TAGAAGTTTATCTGTGTGAACTTCTTGGCTTAGTATTGTTGAGAGGAATCGAGAGATTAGTGCAGTTTAAACAGTTTTTTAGAACGGAAGAAAACCATGA 100 CTAAAAAACCAGGAGGGCCCGGTAAAAACCGGGCTATCAATATGCTGAAACGCGGCATACCCCGCGTATCCCCACTTGTGGGGGTGAAGAGGGTAATTAT 200 GAACTTGCTCGACGGCAGAGGGCCAATACGATTCGTTTTGGCTCTCTTGGCGTTTTTCAATTTCACATCACTAGCCCCGACCAAGGCACTCGTTAGCCGA 300 TGGAAGGCAGTATAGAAAACGTTGCAATGAAACATCTCACCAGTTTCAAAAAGGAACTGGGAACGCTCATCAACGCTGTAAATAAGAGGGGCAAAAAC 400 AAAACAAAAGAGGAGGAAGTAATGGGACAGTCATCTGGATAATGGGCTTGGCAGTTGTGGTTGCCAGTGTGAGTGCAATCAAGCTGTCAAATTTTCAAGG 500 CAAGGTGCTGATGACAATCAACAACACCGATGTGGCTGATGTGATCACCATTCCCACCTCAAAGGGAGGTAAATAGATGTTGGGTCCGAGCTATAGATGTG 600 GGACACATGTGCGAGACACAATCACTTATGAATGCCCAAAGCTTGACGCTGGCAACGACCCGGAGGACATTGACTGCTGGTGCGACAAACAAGCCGTGT 700 ATGTCCAGTATGGACGTTGCACTAGGACCAGGCACTCCAGGAGAAGTAGAAGATCTGTGTCAGTGCAAACCCACGGAGAAAGTTCTTTTAGTGAACAAAA 800 AGAAGCCTGGATGGATTCGACGAAAGCCACTCGGTATCTCATGAAAACAGAGAATTGGATCATACGGAATCCAGGCTATGCTCTTGTGGCAGTGGCACTT 900 GGATGGATGCTTGGTAGCAACAACGGCCAGCGTGTGGTATTCACAATTCTCTTGCTGTTGGTCGCACCCGCATATAGCTTCAACTGCTTAGGTATGGGAA 1000 ATCGTGACTTCATCGAAGGAGTCAGTGGAGCGACGTGGGTGGACCTGGTGCTGGAAGGAGACAGTTGCCTCACCATCATGGCGAACGACAAACCAACATT 1100 GGACGTGCGCATGATAAACATCGAGGCCACGGAACTGGCTGAGGTGCGAACCTACTGCTACCACGCCACAGTGGCTGACATCTCAACAGTGGCAAGATGC 1200 CCCACGACTGGAGAAGCCCATAACACGAAGCGAGCTGACAGCAGCTATGTCTGCAAGCAAGGCTACACTGATCGTGGATGGGGAAACGGATGTGGGTTGT 1300 TTGGGAAAGGCAGCATTGACACATGCGCTAAATTTGTTTGCAGCCACAAGGCCATTGGAAAGATAATCCAGCCAGAAAACATCAAATATGAAGTTGGAGT 1400 GTTTGTTCATGGAACCACAACAGCAGAGAACCACGGAAATTACACAGCCCAGATTGGGGCTTCCCAGGCTGCCAAGTTCACCATCACGCCCAATGCTCCT 1500 TCCATCACTCTGAAGCTTGGAGATTACGGAGAAGTCACGATGGATTGCGAGCCGCGTAGTGGATTTAATACTGAGGCATTTTACGTGCTGACCGTAGGGT 1600 CTAAGTCGTTCCTAGTCCACCGCGAATGGTTCAATGATCTTGCGCTTCCGTGGCTATCTCCATCTAGCACAAATTGGAGAAATAGAGAGATCCTGATGGA 1700 GTTCGAAGAGGCTCACGCGACAAAACAGTCTGTCGTCGCGCTTGGATCACAAGAGGGAGCCTTGCATCAGGCATTGGCTGGTGCCATAGTGGTGGAGTAC 1800 TCTAGCTCAGTGAAGTTGACATCTGGTCACCTCAAATGCAGACTAAGAATGGAGAAGTTGGCGTTGAAAGGGACCACCTATGGTATGTGCACAGAGAAGT 1900 TCTCTTTTTCCAAGAATCCAGCTGACACTGGTCATGGTACGGTTGTCATAGAATTGCAGTACACCGGCACTGACGGACCTTGCAAGATACCCATTTCTTC 2000 GGTGGCCAGTCTGAATGATTTAACTCCAGTTGGTAGATTGGTGACAGTCAATCCTTTTGTTGCCACATCCACCGCCAATTCGAAGGTTTTGGTAGAATTG 2100 GAACCACCATTTGGAGATTCATTCATTGTTGTCGGAAGAGGAGATAAGCAGATCAATCACCATTGGCACAAGGCTGGCAGTTCACTGGGAAAGGCTTTCA 2200 CGACTACTTTGAAAGGAGCTCAGAGGCTGGCAGCCCTTGGTGACACCGCTTGGGACTTTGGATCCATTGGAGGGGTTTTCAATTCCATTGGTAAGGCCGT 2300 GCACCAAGTGTTTGGAGGAGCTTTCAGAACCCTTTTTGGTGGCATGTCCTGGATAACACAAGGATTGATGGGAGCGCTGCTGCTGTGGATGGGTATCAAC 2400 GCACGAGATCGGTCGATTGCACTAGCTTTTCTTGCTACAGGAGGTGTGCTCTTGTTTCTGGCCACCAATGTCCACGCCGATACCGGCTGCGCCATCGATA 2500 TAACCAGAAAAGAAATGAGGTGTGGTAGTGGCATATTTGTGCACAATGACGTGGAGGCTTGGGTTGATAGATACAAGTATCTACCTGAGACTCCCAAGTC 2600 TTTAGCCAAAATAGTCCACAAAGCACACAAGGAAGGCATTTGTGGAGTGAGATCAGTCACCAGACTGGAACACCAAATGTGGGAGGCCGTCAGGGACGAG 2700 TTAAATGTCTTGTTGAAGGAGAATGCGGTAGATCTTAGTGTGGTGGTGGACAAACCATCAGGAAGATACCGACCAGCTCCATTGCGGTTGGCCATGACTC 2800 AGGAAAAGTTTGAGATGGGTTGGAAAGCATGGGGGAAGAGCATTCTCTTTGCGCCGGAACTGGCCAATTCCACGTTTGTGATCGACGGACCTGAAACCAA 2900 AGAGTGTCCAGATGAGCGTAGAGCATGGAACAGCATGCAGATTGAGGATTTTGGGTTTGGCATTACGTCGACTCGAGTGTGGTTGAAGATCAGGGAGGAG 3000 CGCACGAATGAATGTGATGGAGCCATCATCGGCACGGCTGTTAAAGGGAACATGGCAGTGCACAGTGACTTGTCATACTGGATTGAAAGCCATCTCAACG 3100 ACACCTGGAAGCTCGAGAGAGCTGTGTTTGGAGAGATAAAGTCTTGCACTTGGCCAGAAACACACACGCTCTGGGGAGATGGTGTTGAGGAAAGTGAGTT 3200 GATAATTCCACACACACTCGCTGGACCCAAAAGCAAGCATAACAGAAGAGAGGGTTACAAGACACAGAATCAGGGACCATGGGACGAGAGTGAGATCACT 3300 CTTGATTTTGACTACTGTCCAGGGACCACAGTCACCATTGCTGAGGGATGTGGGAAAAGGGGGCCCTCAATCAGGACCACCACTGATAGTGGAAAATTAA 3400 TCACTGATTGGTGTTGCAGGAGCTGCACTTTGCCGCCACTGAGGTTCAGGACAGCCAGTGGGTGCTGGTATGGAATGGAAATACGGCCCATGAAgCATGA 3500 TGAATCCACGCTCGTGAAATCACAAGTCAACGCGTTTAATGGGGAGATGATTGATCCTTTTCAGTTGGGCCTTCTGGTGATGTTTCTGGCCACCCAGGAG 3600 GTCCTTCGCAAGAAGGTGGACGGCCAGACTGACGATTCCTGCGGTTTTGGGGGCCCTACTTGTTCTGATGCTTGGGGGCATCACCTACACTGATCTAGTG 3700 AGATATGTGGTGTTGGTGGCTGCTGCTTTCGCTGAAGCTAACAATGGAGGCGATGTAGTTCATTTGGCCCTGATTGCCGTATTTAAAATCCAACCGGCAT 3800 TCCTAGTCATGAGCATAGCAAGAACAAATTGGACAAACCAGGAAAACATTGCCCTAGTGCTAGGAGCTGCTTTCTTTCAGATGGCCTCAACAGACCTGGA 3900 GTTTGGTATCCATGGGCTGCTAAATGCAGCGGCGACGGCCTGGATGGTAGTGCGGGCGATCACGTTTCCCACGACCTCCACCATCACAATGCCCATACTA 4000 GCTTTGCTGGCGCCAGGAATGAGAGCTCTCCATCTTGACACCTACAGAATCTTTTTGCTTATCATCGGGGTCTGTGCTCTGCTGCATGAAAGGAGGAAAa 4100 aCCATGGCGAAGAAGAAAGGTGCTGTCCTTTTGGGTCTAGCCCTAAGTTCCACTGGGTGGTTTTCACCAGCCATTATGGCAGCTGGGCTCATGGCGTGCA 4200 ATCCAAACAAAAAGAGAGGATGGCCAGCGACAGAATTTCTGTCTGCGATTGGGTTGATGTTTGCTATTGTTGGGGGCCTGGCCGAGTTGGACATCGACTC 4300 TATGGCGATACCTTTCATGTTAGCTGGGCTTATGGCAGTGTCATATGTGGTATCAGGAAAAGCAACGGACATGTGGCTAGAACGTGCGGCCGACATTAGT 4400 TGGGAAGTGGATGCAGCGATCACAGGCAGCAGCCGAAGGTTGGACGTCAAACTAGATGATGATGGAGATTTCCACCTTATTGATGATCCAGGCGTCCCAT 4500 GGAAAATTTGGGTACTGCGCATGTCTTGCATAGGATTGGCGGCCTTCACACCATGGGCCATCATCCCAGCGGCTTTTGGATATTGGCTGACTTTGAAAAC 4600 CACAAAGAGAGGAGGCGTTTTTTGGGACACACCATCACCCAAAGTCTACGCAAAAGGGGACACAACCACAGGAGTGTACAGGATAATGGCTCGAGGGATC 4700 TTTGGCGTCTACCAAGCAGGTGTTGGAGTGATGTATGAGAACGTGTTCCACACTCTGTGGCACACGACCAGAGGAGCTGCCATAATGAGTGGAGAAGGAA 4800 AGTTGACGCCGTACTGGGGAAGCGTTAAGGAGGACCGCATAACTTATGGGGGCCCATGGAGATTCGATCGAAAATGGAATGGAGTGGATGACGTGCAAAT 4900 GATTGTAGTTGAACCAGGAAAAGCAGCTGTAAATGTCCAAACAAAGCCGGGAGTGTTTCGGACTCCACACGGAGAAATTGGAGCTGTTAGCCTGGATTAC 5000 CCTAGTGGGACATCGGGCTCACCCATCCTGGACATCAACGGTGATATCATTGGATTGTATGGGAACGGAGTTGAACTTGGAGATGGCTCATATGTGAGCG 5100 CCATTGTGCAGGGTGAACGGCAAGAAGAGCCCATCCCCGATGCATACAATCCAAACATGCTCAAGAAAAGGCAGCTGACCGTGTTGGACTTGCATCCAGG 5200 ATCTGGGAAAACAAGGAAAATCTTACCCCAAATCATCAAGGATGCCATTCAACAGCGTCTCAGAACAGCTGTTCTGGCGCCCACTCGGGTTGTTGCAGCT 5300 GAGATGGCAGAAGCTCTTAGAGGACTTCCCGTTAGATACCAAACTTCAGCGGTTCCGCGAGAACATCAGGGGAATGAGATAGTTGATGTCATGTGTCACG 5400 CCACCTTAACGCATAAGCTGATGTCACCAAATCGCGTCCCCAATTACAACTTGTTTGTCATGGATGAGGCCCATTTCACAGACCCAGCCAGCATCGCCGC 5500 TAGAGGATACATATCCACCAGAGTGGAATTGGGAGAAGCCGCGGCTATCTTCATGACTGCCACTCCACCAGGAACGACTGACCCCTTCCCTGACTCCAAC 5600 GCTCCCATTCATGATTTGCAGGACGAGATCCCTGACAGAGCATGGAGCAGTGGGTATGAATGGATAACTGAGTACTCTGGGAAGACAGTATGGTTTGTGG 5700 CGAGTGTGAAAATGGGCAACGAAATCGCAGTGTGTCTACAGAGAGCCGGAAAGAGAGTCATCCAGTTAAATCGGAAATCTTATGACACCGAGTACCCCAA 5800 ATGTAAGAATGGGGATTGGGATTTTGTCATCACCACGGACATTTCTGAAATGGGGGCCAACTTTGGAGCGAGCAGAGTGATTGATTGTAGGAAGAGTGTG 5900 AAACCCACCATTCTGGAAGAAGGAGAAGGAAGAGTCATTCTCAGCAACCCATCGCCTATCACCAGTGCGAGTGCAGCCCAGCGGAGAGGCAGAGTGGGCA 6000 GAAATCCAAATCAGGTTGGAGATGAGTACCATTACGGAGGGGTCACAAGTGAAGATGACACCAACCTAGCACACTGGACAGAAGCCAAGATCATGTTGGA 6100 CAACATCCACCTGCCAAATGGGTTGGTAGCTCAGCTCTATGGACCTGAAAGGGAAAAGGCCTTCACAATGGACGGTGAGTATCGATTGAGGGGTGAAGAA 6200 AAGAAGAACTTTCTGGAGTTAATCAGAACAGCCGACCTCCCCGTATGGCTAGCTTACAAAGTGGCTTCAAATGGAATACAGTACACCGATAGGAGATGGT 6300 GTTTTGATGGACCTCGGACGAATGCTATCTTAGAAGACAGCACTGAAGTAGAGATAATCACCAGAACGGGAGAAAGGAAAATTCTAAAACCAAGATGGCT 6400 GGACGCACGGGTGTACGCAGATCACCAGGCTTTGAAGTGGTTTAAGGACTTCGCAGCAGGAAAGAGATCAGCTGTCAGTTTTCTAGAGGTGCTTGGGCGC 6500 ATGCCAGAGCACTTCATGGGGAAAACGCGTGAAGCTCTTGATACAATGTACCTGGTTGCCACGGCAGAAAAAGGGGGAAAAGCTCACCGAATGGCCCTGG 6600 AGGAACTGCCAGATGCACTGGAGACGGTGACACTCATCGCAGCGCTTGCCGTGATGACAGGTGGGTTCTTTCTACTCATGATGCAACGAAAGGGCATAGG 6700 AAAAATGGGCCTCGGGGCTCTCGTGCTCACCCTGGCCACTTTCTTCTTGTGGATGGCAGAGGTCTCAGGGACGAAAATAGCCGGGACCTTACTCATAGCG 6800 TTGCTGCTTATGGTGGTACTCATCCCGGAGCCGGAGAAGCAAAGATCCCAAACGGACAACCAGTTGGCCGTGTTTCTGATCTGCGTCCTCACCGTAGTGG 6900 GAATTGTGGCTGCTAATGAGTATGGCATGCTCGAAAAGACCAAGGAAGACATAAGGAATGTGTTTGGTAACAAGGTTCAGACATCCAATGCACCTGGAAG 7000 CCTATCAAGTCTGGCGCTCGATCTACGACCAGCAACGGCTTGGGCCTTATATGGAGGTAGTACAGTGATTTTAACTCCACTGCTGAAACATTTGATCACC 7100 TCTGAGTATGTGACAACATCACTAGCTTCAATCAACTCACAGGCCGGCTCACTTTTTGTTTTGCCAAAAGGCATGCCTTTCACGGATTTGGATCTGACGG 7200 TTGGACTCGTCTTTCTGGGTTGTTGGGGGCAAATCACTCTCACCACTTTTCTGACAGCTGGAGTGTTAGTAGTTCTGCATTACGGCTATATGCTCCCTGG 7300 CTGGCAAGCTGAAGCCCTGAGGGCAGCTCAGAGACGAACAGCTGCGGGTATCATGAAGAACGCCGTTGTGGATGGGATGGTTGCCACTGATGTGCCTGAA 7400 TTGGAAAGAACAACACCCCTAATGCAGAAGAAGGTGGGGCAAGTGTTGCTAATAGGAGTCAGTATAGCAGCTTTTCTTGTCAATCCCAATGTCACCACCG 7500 TGCGAGAAGCCGGTGTGCTGGTGACCGCTGCTACGCTCACCCTATGGGATAATGGAGCAAGTGCCGTCTGGAATTCAACTACAGCCACAGGACTCTGCCA 7600 CGTCATGCGAGGCAGTTACTTGGCTGGTGGTTCAATAGCTTGGACTCTCATCAAGAATGTTGATAAACCATCCTTGAAAAGAGGAAGGCCTGGAGGAAGA 7700 ACGCTGGGTGAGCAATGGAAAGAAAAATTGAACGCCATGAACAAAGAAGAGTTTTTCAGGTACAGGAAAGAAGCCATAGTTGAGGTGGACCGCACAGAGG 7800 CACGCAGGGCTAGACGAGAGAATAACAAAGTGGGAGGTCATCCCGTGTCACGAGGTTCAGCAAAGCTCCGATGGATGGTGGAGAAAGGGTTTGTCTCCCC 7900 TGTTGGAAAGGTTGTGGACCTTGGCTGTGGGCGGGGAGGATGGTGCTATTATGCTGCCACTCTGAAAAAAGTGCAAGAAGTTAAAGGTTATACAAAAGGA 8000 GGGGCCGGACATGAGGAACCGATGCTGATGCAAAGCTATGGTTGGAATCTGGTCACGATGAAGAGTGGAGTGGATGTGTTCTACAGACCTTCAGAGCCTA 8100 GTGACACCCTGCTCTGTGACATAGGGGAGTCTTCTCCAAGTCCAGACGTCGAGGAGCAACGCACTCTGCGGGTTCTGGAAATGGCATCAGAGTGGCTACA 8200 CCGAGGACCCAGAGAATTCTGCATTAAAGTTTTGTGTCCATACATGCCAAAGGTGATAGAAAAGATGGAAACGCTACAACGTCGCTTTGGAGGCGGACTG 8300 GTGCGCGTTCCCCTGTCACGCAACTCAAATCACGAAATGTACTGGGTTAGTGGGGCTGCTGGGAACGTGGTACATGCTGTAAACATGACCAGTCAAGTTT 8400 TGCTGGGGCGAATGGACCGACCAGTCTGGAGAGGACCCAAATATGAAGAAGATGTCAACTTGGGAAGCGGGACCAGAGCTGTAGGGAAAGGTGAGGTTCA 8500 CAGTGACCAAGGAAAAATCAAGAAGCGGATAGAGAAGCTGAAAGAAGAGTATGCAGCGACGTGGCACGAGGACCCTGAACATCCATACCGCACTTGGACA 8600 TACCATGGAAGCTATGAAGTGAAGGCCACCGGTTCAGCCAGCTCCCTTGTCAACGGAGTGGTTAAGCTCATGAGTAAACCTTGGGATGCCATCACTAGTG 8700 TCACCACCATGGCCATGACTGACACTACTCCCTTTGGTCAGCAGAGAGTCTTCAAAGAAAAAGTTGACACCAAGGCGCCTGAGCCACCTGCAGGAGTTCG 8800 GGAAGTGCTGGACGAAACTACCAACTGGCTGTGGGCCTACTTGTCAAGAGAGAAAAGACCTCGCTTGTGTACGAGAGAGGAGTTCATCCGGAAAGTCAAC 8900 AGCAACGCAGCTCTTGGAGCCATGTTTGCCGAGCAAAATCAGTGGAGCTCAGCCAGGGAGGCTGTTAGTGACCCGGCCTTCTGGAACATGGTCGACATTG 9000 AAAGAGAGAACCACCTACGAGGGGAGTGCCACACCTGCATCTACAACATGATGGGAAAAAGAGAAAAGAAACCTGGTGAGTTTGGGAAGGCTAAAGGAAG 9100 CAGAGCTATCTGGTTCATGTGGCTCGGAGCCCGCTACCTGGAATTCGAGGCACTCGGGTTCCTGAACGAGGACCATTGGCTGAGCAGGGAGAACTCTGGA 9200 GGAGGAGTGGAAGGCTCAGGCATACAGAAGCTAGGGTACATTTTGCGAGACATCTCAACGAAATCTGGAGGGAAAATGTATGCTGATGACACCGCAGGCT 9300 GGGACACTAGGATCACAAGGGTTGATCTGGACAATGAGGCAAAGGTGCTGGAACTTCTGGATGGGGAGCACAGGATGTTGGCCCGTGCTATTATAGAATT 9400 GACTTACAAACACAAAGTTGTCAAAGTAATGAGGCCAGCAGTAGGTGGAAAGACCGTGATGGATGTGATCTCTAGAGAAGATCAAAGAGGGAGTGGGCAA 9500 GTGGTCACATATGCTCTCAACACCTTCACAAACATAGCTGTCCAGCTAGTGAGGTTGATGGAGGCTGAAGGGGTTGTCGGTCCACAGGATGTGGAGCAGC 9600 TCCCCAGGAAAACCAAATTCGCAGTCAGGACATGGCTTTTTGAAAATGGAGAAGAGAGAGTCACCAGAATGGCAGTGAGTGGGGATGACTGCGTTGTCAA 9700 ACCTTTGGATGACAGATTCGCGCATGCTTTACACTTCTTGAATGCGATGTCAAAGGTGAGGAAAGACATACAAGAATGGAAGCCATCTCAAGGCTGGCAC 9800 GACTGGCAGCAAGTCCCTTTCTGCTCGAACCACTTTCAGGAGATTGTGATGAAGGATGGTAGAAGCCTTGTTGTGCCCtGCCGGGGACAGGATGAGTTAA 9900 TAGGCAGGGCCCGGATTTCACCAGGAGCAGGATGGAATGTGAGAGACACAGCCTGCCTAGCTAAGGCCTACGCCCAAATGTGGCTCCTCCTCTACTTTCA 10000 CCGGAGAGACTTGCGCCTTATGGCCAACGCGATCTGCTCAGCCGTTCCGGTAGACTGGGTACCCACAGGTAGGACATCATGGTCGATACACTCAAAAGGA 10100 GAGTGGATGACAACAGAAGACATGCTGCAGGTGTGGAACAGGGTATGGATTGAGGAGAATGAATGGATGAGAGACAAAACCCCCGTCGCCAGTTGGACCG 10200 ACGTCCCATACGTCGGAAAGAGGGAAGACATCTGGTGCGGCAGCTTGATCGGAACGCGGACAAGGGCCACCTGGGCAGAAAACATCTATGCAGCAATAAA 10300 CCAAGTGAGAGCAATAATTGGAAATGAAAAGTATGTGGACTACATGACATCACTTAGGAGGTATGAAGACACTTTGGTCCAGGAAGATAGAGTAATTTAA 10400 AAAACTTTTGGTAATGAGTGTAAATAGTAGTATTTATTGTAAATAGTGTAAATAAACAAATTTAAATAGGAAGTCAGGCCGACGTAAGTCGCCACCGGAT 10500 GCTGAGTAGACGGTGCTGCCTGCGCCTCAGCCCCAGGAGGACTGGGTTAACAAATCTGACAACCGAAGGTAGGAAAGCCCTCAAAACCGTCTCGGAAGAA 10600 GGTCCCTGCTTACTGGAGGTTGGAAGACCGTGTCAGGCCACGCAAGTGCCACTTCGCTGAGGAGTGCAGCCTGTACAGCCCCGGGAGGACCGGGTAAACA 10700 AAGCCGATGAGGCCCCCACGGCCCAAACCTCATCCAGGATGCAATGGATGAGGCGTAAGGACTAGAGGTTAGAGGAGACCCCGTGGAAAAGAAAATGCGG 10800 CCCAAACTCTTTcGAAGCTGTAGAAGGAGTGGAAGGACTAGAGGTTAGAGGAGACCCCGCATTTGCATCAAAACAGCATATTGACACCTGGGATTAGACT 10900 AGGAGATCTTCTGATCTATCTCAACATCAGCTACAAGGCACAGAGCGCCGAAATATGTAGCTGGTGGTGGGGAAGAACACAGGATCT 10987
[0031] <Example 4>Confirmation of Immunogenicity of K15P38 and K15P38-KNIH 1) Immunogenicity Analysis Using ELISA Assay Mice were immunized with K15P38 and K15P38-KNIH viruses, and serum was collected. After immunization with each virus, serum obtained was used to perform ELISA to confirm the immunoglobulin G (IgG) production and cross-reactive immunogenicity of serum against each virus. The original Japanese encephalitis virus (K15P38) or K15P38-KNIH virus before cell passage was attached (coated) to an ELISA plate, and the virus-specific immunoglobulin G (IgG) production of the immune serum against each cell passage virus (K15P38-V25) or mouse brain passage virus (K15P38-KNIH) was compared. It was confirmed that there was no difference in the immunogenicity of the cell passage virus and the brain passage virus (Figure 2).
[0032] - We confirmed that there was no difference in antibody responses to the original isolate between the two subculture methods (Figure 2A), and that the immunogenicity to the brain-passaged virus was similar with no significant difference (Figure 2B).
[0033] 2) Neutralizing antibody formation analysis using the PRNT (Plaque Reduction Neutralization Test) analysis method Using mouse serum immunized with Japanese encephalitis virus K15P38-KNIH, neutralizing antibody titers (ND) against the original virus (K15P38) and high-titer virus (K15P38-KNIH) were measured. 50 , Karber formula) were compared.
[0034] We confirmed that mouse sera obtained by immunization with the K15P38-KNIH virus strain had an effective neutralizing ability against the original virus that was comparable to that of the high-titer virus (Figure 3).
[0035] - Neutralizing antibodies produced after immunization with high-titer virus (K15P38-KNIH) were confirmed to have effective neutralizing ability against the original isolate and high-titer virus, and it was confirmed that some gene mutations do not have a significant effect on immunogenicity.
[0036] 3) Confirmation of immunogenicity of vaccine candidate substances using an animal model (BALB / C) We secured inactivated antigens of the vaccine strain genotype III (Beijing) and the vaccine candidate substance type V (K15P38-KNIH) used in the Japanese encephalitis virus immunogenicity experiment.
[0037] In the Japanese encephalitis virus genotype III and V antigen (8ug / dose) vaccination groups, when the same antigen was administered twice, an increase in immunoglobulin and antibody titers (total IgG) was confirmed, and there was no significant difference in the immunogenicity of the inactivated antigen (Figure 4).
[0038] Neutralizing antibody titers (ND50, Karber formula) were determined using mouse serum induced by genotype V immune antigen, and it was found that the neutralizing ability against genotype III was significantly lower than that against genotype V virus, which suggests that cross-protection between genotypes is low.
[0039] Although the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0040] [Accession number] Name of depository institution: Biological Resource Center Deposit number: KCTC150277BP Entrustment date and time: July 8, 2022 JPEG2024541677000003.jpg239170
Claims
1. High titer Japanese encephalitis virus genotype V K15P38-KNIH.
2. The Japanese encephalitis virus genotype V type K15P38-KNIH according to claim 1, characterized in that the Japanese encephalitis virus contains the gene of sequence number 1.
3. The Japanese encephalitis virus genotype V K15P38-KNIH according to claim 1, characterized in that the Japanese encephalitis virus is produced by inoculation into the mouse cerebrum.
4. The high titer is 1×10 8 The Japanese encephalitis virus genotype V K15P38-KNIH according to claim 1, characterized in that the virus is in a concentration of 0.01 pfu / mL or more.
5. Inoculating the isolated Japanese encephalitis virus into the mouse brain; and Obtaining Japanese encephalitis virus from mouse cerebrum; The present invention relates to a method for producing high-titer Japanese encephalitis virus genotype V K15P38-KNIH, comprising the steps of:
6. The method for producing high-titer Japanese encephalitis virus genotype V K15P38-KNIH according to claim 5, wherein the isolated Japanese encephalitis virus is Japanese encephalitis virus genotype V.
7. The method for producing high-titer Japanese encephalitis virus genotype V K15P38-KNIH according to claim 5, further comprising a step of subculturing the virus in Vero cells.
8. The method for producing high-titer Japanese encephalitis virus genotype V K15P38-KNIH according to claim 5, characterized in that the inoculation is performed twice or more.
9. A vaccine composition comprising the Japanese encephalitis virus according to any one of claims 1 to 4.
10. 10. The vaccine composition of claim 9, further comprising a pharma- ceutically acceptable carrier or excipient.
11. A vaccination method against Japanese encephalitis, comprising the step of administering the vaccine composition according to claim 9 to a non-human animal.
Citation Information
Patent Citations
Production of hemorrhagic fever with renal syndrome virus antigen and vaccine and diagnostic agent using said antigen
JP1989056620A
Attenuated Japanese encephalitis virus adapted for Vero cells and Japanese encephalitis vaccine
JP2001514844A
Vaccine for japanese encephalitis viruses, and production method thereof
JP2018095660A
Attenuated genotype 1 Japanese encephalitis vaccine composition containing the same for preventing Japanese encephalitis in swine
KR101642705B1
Inactivated vaccine composition for Japanese Encephalitis comprising Japanese encephalitis virus KV1899 strain antigen inactivated by binaryethyleneimine and swine GM-CSF recombinant protein
KR101484605B1
